Joshua Silverman
CIK 1524858 · Chief Executive Officer · last filed 2026-10-16
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AYRO price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
205 EAST 42ND ST - 20TH FL.
NEW YORK, NY 10017
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| FABC | Chief Executive Officer | 235,937 | $1.70 | $401.1K | $0 | 2 | 2026-10-16 |
| QCLS | Executive Chairman | 116,835 | $0.37 | $43.2K | $0 | 5 | 2026-10-02 |
| TAOX | Executive Chairman | 126,681 | $2.72 | $344.6K | $0 | 3 | 2026-05-19 |
| PMCB | CEO and President | 466,250 | $0.41 | $189.8K | $80.5K | 3 | 2026-01-07 |
| StableX Technologies, Inc. (SBLX) Delisted | Chief Executive Officer | — | $3.10 | — | $0 | 1 | 2025-10-31 |
| FEMY | Director | — | $1.42 | — | $0 | 3 | 2025-06-27 |
| Petros Pharmaceuticals, Inc. (PTPI) Delisted | Director | 40,449 | $0.01 | $251 | $0 | 9 | 2025-02-21 |
| StableX Technologies, Inc. (AYRO) Delisted | Executive Chairman | 11,842 | $7.08 | $83.8K | -$237.8K | 11 | 2024-12-02 |
| TAO Synergies Inc. (SNPX) Delisted | Director | 1,530 | $24.55 | $37.6K | $60.7K | 10 | 2024-04-10 |
| Q/C TECHNOLOGIES, INC. (MYMD) Delisted | Director | 2,959 | $1.82 | $5.4K | $103.4K | 4 | 2023-06-09 |
| NTRP | Director | 0 | $1.15 | $0 | $107.8K | 9 | 2020-12-03 |
| Q/C TECHNOLOGIES, INC. (AKER) Delisted | Director | 2,600 | $4.94 | $12.8K | $0 | 3 | 2020-09-11 |
| StableX Technologies, Inc. (DCAR) Delisted | Director | 7,577 | — | — | $37.9K | 5 | 2019-08-29 |
| Marker Therapeutics, Inc. (TPIV) Delisted | Director | 170,554 | — | — | $0 | 4 | 2018-10-17 |
| StableX Technologies, Inc. (WPCS) Delisted | Director | — | — | — | $0 | 1 | 2017-05-02 |
| NATIONAL HOLDINGS CORP (NHLD) Delisted | Director | 828,646 | $3.25 | $2.69M | $0 | 1 | 2016-09-13 |
| XWELL, Inc. (VRNG.WS) Delisted | 10%+ Owner | 902,203 | — | — | -$5.5K | 2 | 2011-12-19 |
Recent Filings · Page 2 of 9
88 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-11-14 | QCLS | Grant (A) | +91,356 | $0 | EDGAR |
| 2025-10-31 | StableX Technologies, Inc. (SBLX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-10-17 | TAOX | Mixed | +60,000 | -$289.2K | EDGAR |
| 2025-10-06 | QCLS | Grant (A) | +8,644 | $0 | EDGAR |
| 2025-07-02 | TAOX | Mixed | +25,151 | -$131.6K | EDGAR |
| 2025-06-27 | FEMY | Grant (A) | — | $0 | EDGAR |
| 2025-02-21 | Petros Pharmaceuticals, Inc. (PTPI) Delisted | Grant (A) | +1,000,000 | $0 | EDGAR |
| 2024-12-02 | StableX Technologies, Inc. (AYRO) Delisted | Mixed | +139,886 | $0 | EDGAR |
| 2024-07-15 | FEMY | Grant (A) | — | $0 | EDGAR |
| 2024-04-10 | TAO Synergies Inc. (SNPX) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.